<DOC>
	<DOC>NCT01471834</DOC>
	<brief_summary>The purpose of this clinical investigation is to verify the efficacy and safety of the CVRx Barostim Neo System in the treatment of resistant hypertension.</brief_summary>
	<brief_title>Barostim Neo System in the Treatment of Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Age at least 21 years and no more than 80 years Resistant hypertension despite optimal, stable antihypertensive medications for at least 4 weeks Significant carotid plaque or stenosis Known or suspected baroreflex failure or autonomic neuropathy Significant renal disease requiring dialysis Myocardial infarction, unstable angina, syncope, or cerebral vascular accident within the past 3 months Secondary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>